Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly announces start of phase III Alzheimer’s trial

Eli Lilly announces start of phase III Alzheimer’s trial

3rd October 2008

Healthcare company Eli Lilly has commenced the third stage of global testing for a potential new treatment for Alzeimer’s disease.

Phase III of the trial process for the company’s LY450139 a gamma-secretase inhibitor will consist of a real-world dosing simulation of 1,100 patients from 22 countries.

Dubbed IDENTITY 2, the third-phase study aims to prove LY450139 can aid the treatment of patients suffering from mild to moderate forms of the condition by delaying its further progression.

Dr Eric Siemers, medical director of Alzheimer’s disease research at Eli Lilly, commented: “IDENTITY 2 is a study that we believe will give us additional insights into how LY450139 might best be given to patients in real clinical situations.”

The treatment – intended to be a once-a-day oral supplement – is based on a current theory that Alzheimer’s disease is caused by the clumping together of amyloid beta subtypes, which slowly destroy brain cells.

By controlling or blocking the enzyme gamma secretase, which can produce amyloid beta, researchers hope to reduce the onset of the disease.

Eli Lilly’s Zypadhera treatment for schizophrenia was recently recommended for European Commission approval by the Committee for Medicinal Products for Human Use.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.